Pharming « Terug naar discussie overzicht

quote:

kammetje schreef op 29 januari 2015 19:25:

[...]

Dow Jones 17,221.33 0.17%
Nasdaq 4,622.19 -0.34%
Healthcare -0.11%
SLXP 135.03 5.58%


135.03 +7.14 (5.58%)
Real-time: 1:08PM EST
NASDAQ real-time data - Disclaimer
Currency in USD

quote:

Hoopmazzel schreef op 29 januari 2015 19:02:

Als de Pharmingkoers zich weer gedraagd als de eerste de beste ballentent,dan hebben we gelukkig Salix nog.....
En wat zegt de Salix stijging nu in relatie met Pharming?.

Geen bal!

quote:

lower schreef op 28 januari 2015 23:12:

Salix to restate financials 2013 and 2014

• After an accounting review by the Board's Audit Committee, in consultation with others, Salix Pharmaceuticals (NASDAQ:SLXP) announces that its financial statements for 2013 and the first three quarters of 2014 contain errors and should no longer be relied upon. The errors are primarily related to the timing of the recognition of certain revenue, revenue-reducing returns and discounts and expense items.
• The corrections will reduce net product revenue and net income $20.1M and $11.8M ($0.18 per share), respectively, for 2013. For the first three quarters of 2014, net product revenues will be reduced by $0.7M with no change in net loss.
• Salix expects to file the revised statements with the SEC prior to filing its 10-K on or before March 2.
• Investors appear unconcerned. Shares are up 1% after hours on light volume.

quote:

lower schreef op 29 januari 2015 19:33:

[...]

SLXP received upwardly revised price targets from Jefferies (to $149) and Cantor (to $151), after the company said it will restate its financial statements for the past seven quarters. The stock has had a strong start to the year, up 16%, and this morning has added 3.7% to trade at $132.98. However, six out of 14 analysts covering the shares maintain a tepid "hold" recommendation, and the average 12-month price target of $130.69 stands at a discount to the equity's current perch. If Salix Pharmaceuticals, Ltd. continues to outperform, a fresh wave of upgrades and/or price-target hikes could help fuel its fire.

===================
Restaten en hogere waardering van een paar analisten.
Ze zouden een dikke boete moeten krijgen! Ik vind het echt raar dat dat "restaten" kan.

Wat vinden jullie?

quote:

Hoopmazzel schreef op 29 januari 2015 19:28:

[...]

kammie belegt in salix.fijn te weten!

quote:

kammetje schreef op 29 januari 2015 20:08:

[...]

???????????????????????????

quote:

Hoopmazzel schreef op 29 januari 2015 21:13:

[...]

sloof je niet zo uit, kammie. één is genoeg.je bent niet aant stofzuigen...

quote:

stormvogel schreef op 30 januari 2015 09:46:

www.devicespace.com/News/salix-pharma...